Welcome to our dedicated page for Milestone Pharmaceuticals SEC filings (Ticker: MIST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Milestone Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Milestone Pharmaceuticals's regulatory disclosures and financial reporting.
Milestone Pharmaceuticals Inc. reported results from its 2026 annual shareholder meeting. Shareholders approved an amendment to the 2019 Equity Incentive Plan that increases the number of ordinary shares authorized for issuance by 6,800,000 shares, expanding the pool available for future equity-based compensation.
All eight director nominees were elected, each receiving roughly 23.4–24.2 million votes for and about 3.1–3.9 million votes withheld, with 48.6 million broker non-votes recorded per nominee. Shareholders also ratified PricewaterhouseCoopers LLP as auditor with 75,025,285 votes for, 249,836 against and 664,912 abstentions.
They approved the amended 2019 Equity Incentive Plan with 19,262,773 votes for, 5,479,043 against, 2,617,059 abstentions and 48,581,158 broker non-votes. In a non-binding advisory vote on executive pay, 19,665,705 votes supported the compensation of named executive officers, 6,990,920 were against, 702,247 abstained and 48,581,161 were broker non-votes.
Milestone Pharmaceuticals Inc. director Lisa M. Giles received a grant of stock options covering 77,000 shares of common stock. The options have an exercise price of $1.2200 per share and expire on June 10, 2036. They vest in twelve equal monthly installments starting July 10, 2026, or will be fully vested by the next annual stockholder meeting if she continues providing service.
Milestone Pharmaceuticals director Seth H. Z. Fischer received a grant of stock options covering 77,000 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 10, 2036. They vest in twelve equal monthly installments starting July 10, 2026, or will be fully vested by the next annual stockholder meeting if he continues serving.
Milestone Pharmaceuticals Inc. director Duty Stuart received a grant of stock options covering 77,000 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 10, 2036. Following this grant, Stuart holds options on 77,000 shares.
The award vests in twelve equal monthly installments starting on July 10, 2026, and will in any case be fully vested on the date of the next annual stockholders’ meeting, as long as Stuart continues providing service through each vesting date.
Milestone Pharmaceuticals director Robert James Wills reported a grant of stock options for 77,000 shares of Common Stock. The options have an exercise price of $1.22 per share and expire on June 10, 2036. This is a compensation-related award, not an open-market purchase.
The option vests in twelve equal monthly installments beginning on July 10, 2026, and will in any case be fully vested on the date of the next annual meeting of stockholders, as long as Wills continues providing service through each vesting date. Following this grant, he holds 77,000 option-based rights directly.
Milestone Pharmaceuticals Inc. director Michael John Tomsicek received a grant of stock options covering 77,000 shares of common stock at an exercise price of $1.22 per share. The options vest in twelve equal monthly installments beginning on July 10, 2026, and will in any case be fully vested by the date of the next annual stockholders’ meeting, as long as he continues to provide service. Following this grant, he holds 77,000 stock options directly, which are scheduled to expire on June 10, 2036.
Milestone Pharmaceuticals Inc. director Andrew Saik received a grant of stock options as part of his compensation. The award covers 77,000 options to buy common stock at an exercise price of $1.22 per share.
The options vest in twelve equal monthly installments starting on July 10, 2026, and will in any case be fully vested by the date of the company’s next annual stockholder meeting, as long as Saik continues to provide service through each vesting date. Following this grant, he holds 77,000 options directly.
Milestone Pharmaceuticals Inc. director Joseph C. Papa received a grant of stock options covering 77,000 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 10, 2036. They vest in twelve equal monthly installments beginning on July 10, 2026, or will in any case be fully vested by the date of the next annual meeting of stockholders, as long as he continues providing service. Following this grant, he holds 77,000 options directly.
RTW Investments and Roderick Wong reported beneficial ownership of 12,356,953 common shares of Milestone Pharmaceuticals, representing 9.99% of the class. The cover pages assume exercise of warrants to purchase 6,025,952 shares subject to a 9.99% beneficial ownership cap.
The filing bases percentages on 117,667,277 shares outstanding as of March 20, 2026. The Reporting Persons state shared voting and dispositive power over the 12,356,953 shares. The statement is an amended Schedule 13G/A signed on May 15, 2026.